Founded in 2018, Nutcracker Therapeutics is bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics through its push-button mRNA synthesis and formulation platform. Armed with this high-tech advantage, we will advance mRNA therapeutics into the clinic and engage in strategic partnerships with clinical institutions and pharmaceutical/biotech companies. Our GMP-in-a-box approach to manufacturing is expected to offer significant cost, cycle time, capacity and point-of-care execution advantages over other RNA manufacturing approaches. Supporting our initial focus on mRNA therapeutics for oncology, our platform will ultimately enable the development and manufacturing of all RNA therapeutics to benefit patients worldwide.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/24/20 | $60,000,000 | Series B |
ARCH Venture Partners Bluebird Ventures | undisclosed |
| 03/14/22 | $167,000,000 | Series C |
ARCH Venture Partners | undisclosed |
